Talotrexin

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameTalotrexin
Drug Alias Nametalotrexine他洛曲新talotrexinaTalopterintalotrexinum +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydrofolate reductase inhibitors
TargetsDihydrofolate reductase
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesRussian Federation
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAsh StevensDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteNational Cancer InstituteSpectrum Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorSolid tumoursCarcinoma, Non-Small-Cell Lung +[6] 

Other Information

ATC CodeN/A
Related LinksN/A